- Home
- FRD vs CHRS Comparison
FRD vs CHRS Comparison
Compare FRD & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRD
- CHRS
- Stock Information
- Founded
- FRD 1965
- CHRS 2010
- Country
- FRD United States
- CHRS United States
- Employees
- FRD N/A
- CHRS N/A
- Industry
- FRD Steel/Iron Ore
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FRD Industrials
- CHRS Health Care
- Exchange
- FRD Nasdaq
- CHRS Nasdaq
- Market Cap
- FRD 159.1M
- CHRS 186.0M
- IPO Year
- FRD N/A
- CHRS 2014
- Fundamental
- Price
- FRD $22.64
- CHRS $1.21
- Analyst Decision
- FRD
- CHRS Strong Buy
- Analyst Count
- FRD 0
- CHRS 4
- Target Price
- FRD N/A
- CHRS $4.51
- AVG Volume (30 Days)
- FRD 18.2K
- CHRS 1.3M
- Earning Date
- FRD 11-10-2025
- CHRS 11-06-2025
- Dividend Yield
- FRD 0.71%
- CHRS N/A
- EPS Growth
- FRD 43.48
- CHRS N/A
- EPS
- FRD 1.63
- CHRS 1.34
- Revenue
- FRD $510,450,000.00
- CHRS $277,728,000.00
- Revenue This Year
- FRD N/A
- CHRS N/A
- Revenue Next Year
- FRD N/A
- CHRS $109.48
- P/E Ratio
- FRD $13.88
- CHRS $2.26
- Revenue Growth
- FRD 8.72
- CHRS 152.07
- 52 Week Low
- FRD $12.24
- CHRS $0.70
- 52 Week High
- FRD $23.50
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- FRD 59.57
- CHRS 31.20
- Support Level
- FRD $20.15
- CHRS $1.23
- Resistance Level
- FRD $23.50
- CHRS $1.39
- Average True Range (ATR)
- FRD 1.16
- CHRS 0.13
- MACD
- FRD 0.14
- CHRS -0.05
- Stochastic Oscillator
- FRD 74.07
- CHRS 13.29
About FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.